In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to establish Protected dosing program. Supplemental individuals are going to be enrolled on the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase https://hilairem776zku9.mycoolwiki.com/user